Olga Valota

1.3k total citations
43 papers, 891 citations indexed

About

Olga Valota is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Olga Valota has authored 43 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Olga Valota's work include Renal cell carcinoma treatment (19 papers), Renal and related cancers (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Olga Valota is often cited by papers focused on Renal cell carcinoma treatment (19 papers), Renal and related cancers (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Olga Valota collaborates with scholars based in Italy, United States and France. Olga Valota's co-authors include Robert J. Motzer, Robert A. Figlin, Thomas E. Hutson, Gary R. Hudes, Michelle Casey, Brad Rosbrook, Neeraj Agarwal, Akintunde Bello, Hariharan Subramanian and Bridget Martell and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Olga Valota

40 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olga Valota Italy	14	563	436	346	258	118	43	891
Andrea Marchetti Italy	13	629 1.1×	369 0.8×	564 1.6×	276 1.1×	202 1.7×	48	1.2k
Vesna Šneller United States	7	582 1.0×	584 1.3×	360 1.0×	361 1.4×	102 0.9×	12	995
Matteo Rosellini Italy	14	673 1.2×	389 0.9×	590 1.7×	293 1.1×	203 1.7×	49	1.2k
Yifah Yaron United States	11	382 0.7×	336 0.8×	615 1.8×	149 0.6×	115 1.0×	17	1.4k
Alessia Mennitto Italy	19	479 0.9×	271 0.6×	549 1.6×	225 0.9×	212 1.8×	59	1.0k
Jakub Żołnierek Poland	11	788 1.4×	617 1.4×	442 1.3×	452 1.8×	98 0.8×	23	1.1k
Beata Korytowsky United States	17	617 1.1×	370 0.8×	565 1.6×	250 1.0×	78 0.7×	78	1.1k
Jiří Tomášek Czechia	16	834 1.5×	524 1.2×	680 2.0×	418 1.6×	187 1.6×	61	1.4k
Gonzalo Recondo United States	15	576 1.0×	386 0.9×	637 1.8×	313 1.2×	80 0.7×	54	1.1k
Stephanie Cardarella United States	11	901 1.6×	431 1.0×	573 1.7×	303 1.2×	77 0.7×	13	1.1k

Countries citing papers authored by Olga Valota

Since Specialization

Citations

This map shows the geographic impact of Olga Valota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Valota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Valota more than expected).

Fields of papers citing papers by Olga Valota

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Valota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Valota. The network helps show where Olga Valota may publish in the future.

Co-authorship network of co-authors of Olga Valota

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Valota. A scholar is included among the top collaborators of Olga Valota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Valota. Olga Valota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laurentiis, Michelino De, Xin Hu, Marina Elena Cazzaniga, et al.. (2025). 489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial. Annals of Oncology. 36. S380–S381. 1 indexed citations

Telli, Melinda L., Wei Mo, Amita Patnaik, et al.. (2024). 264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 9. 103285–103285. 3 indexed citations

Motzer, Robert J., Jean‐François Martini, Xinmeng Jasmine Mu, et al.. (2022). Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. Nature Communications. 13(1). 5959–5959. 7 indexed citations

George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research. 25(4). 1165–1173. 18 indexed citations

Rini, Brian I., Bernard Escudier, Jean-François Martini, et al.. (2018). Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. Clinical Cancer Research. 24(18). 4407–4415. 45 indexed citations

Gross‐Goupil, Marine, Tae‐Geon Kwon, Masatoshi Eto, et al.. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of Oncology. 29(12). 2371–2378. 176 indexed citations

Rini, Brian I., Thomas E. Hutson, Robert A. Figlin, et al.. (2018). Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical Genitourinary Cancer. 16(4). 298–304. 42 indexed citations

Patel, Sandip Pravin, Nathan A. Pennell, Suchita Pakkala, et al.. (2016). Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449. 2 indexed citations

Kang, Yoon‐Koo, Thomas Yau, Ho Yeong Lim, et al.. (2015). Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Annals of Oncology. 26(12). 2457–2463. 78 indexed citations

10.

Motzer, Robert J., Thomas E. Hutson, Gary R. Hudes, et al.. (2014). Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 74(4). 739–750. 56 indexed citations

11.

Oh, Do‐Youn, Reza Khosravan, Xun Lin, et al.. (2013). Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Investigational New Drugs. 31(6). 1547–1558. 20 indexed citations

12.

Sessa, Cristiana, Olga Valota, & Cristina Geroni. (2007). Ongoing phase I and II studies of novel anthracyclines. Cardiovascular Toxicology. 7(2). 75–79. 17 indexed citations

13.

Geroni, Cristina, Olga Valota, Maja J.A. de Jonge, et al.. (2003). Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation. European Journal of Cancer. 39(5). 675–683. 8 indexed citations

14.

Jonge, Maja J.A. de, Jaap Verweij, Ate van der Gaast, et al.. (2002). Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. European Journal of Cancer. 38(18). 2407–2415. 4 indexed citations

15.

Fokkema, Eelco, Jaap Verweij, A.T. van Oosterom, et al.. (2000). A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. British Journal of Cancer. 82(4). 767–771. 9 indexed citations

16.

Miotti, Silvia, Donatella Negri, Olga Valota, et al.. (1999). Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. International Journal of Cancer. 84(1). 62–68. 35 indexed citations

17.

Jacobs, Nathalie, Alessandra Mazzoni, Delia Mezzanzanica, et al.. (1997). Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunology Immunotherapy. 44(5). 257–264. 14 indexed citations

18.

Valota, Olga, et al.. (1996). Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies. European Journal of Cancer. 32(3). 498–505. 4 indexed citations

19.

Negri, Donatella, Olga Valota, Silvano Ferrini, et al.. (1995). In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. British Journal of Cancer. 72(4). 928–933. 25 indexed citations

20.

Valota, Olga, Donatella Negri, Alessandra Mazzoni, et al.. (1995). Anti‐tumor efficacy of an anti‐epidermal‐growth‐factor‐ receptor monoclonal antibody and its F(ab′)₂ fragment against high‐ and low‐egfr‐expressing carcinomas in nude mice. International Journal of Cancer. 62(5). 643–650. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact